Total Payments
$36,310
2024 Payments
$122.53
Companies
11
Transactions
70
Medicare Patients
978
Medicare Billing
$304,898
Payment Breakdown by Category
Other$14,550 (40.1%)
Consulting$14,501 (39.9%)
Travel$3,213 (8.8%)
Research$2,260 (6.2%)
Food & Beverage$1,785 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,550 | 10 | 40.1% |
| Consulting Fee | $14,501 | 7 | 39.9% |
| Travel and Lodging | $3,213 | 13 | 8.8% |
| Unspecified | $2,260 | 16 | 6.2% |
| Food and Beverage | $1,785 | 24 | 4.9% |
Payments by Type
General
$34,049
54 transactions
Research
$2,260
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $21,604 | 24 | $0 (2021) |
| Amgen Inc. | $11,596 | 19 | $0 (2023) |
| Gilead Sciences, Inc. | $1,311 | 15 | $0 (2019) |
| Otsuka Pharmaceutical Co., Ltd. | $949.78 | 1 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $282.03 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $158.59 | 2 | $0 (2021) |
| Mallinckrodt LLC | $124.60 | 1 | $0 (2018) |
| PFIZER INC. | $122.42 | 1 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $117.39 | 1 | $0 (2022) |
| OPKO Pharmaceuticals, LLC | $25.74 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $122.53 | 2 | Otsuka America Pharmaceutical, Inc. ($103.77) |
| 2023 | $103.67 | 1 | Amgen Inc. ($103.67) |
| 2022 | $200.63 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($117.39) |
| 2021 | $3,293 | 4 | AstraZeneca Pharmaceuticals LP ($3,134) |
| 2020 | $18,687 | 24 | AstraZeneca Pharmaceuticals LP ($18,470) |
| 2019 | $1,311 | 15 | Gilead Sciences, Inc. ($1,311) |
| 2018 | $2,000 | 5 | Otsuka Pharmaceutical Co., Ltd. ($949.78) |
| 2017 | $10,592 | 17 | Amgen Inc. ($10,592) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/30/2024 | Baxter Healthcare | — | Food and Beverage | In-kind items and services | $18.76 | General |
| 01/18/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $103.77 | General |
| Category: NEPHROLOGY | ||||||
| 10/25/2023 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $103.67 | General |
| Category: Nephrology | ||||||
| 12/08/2022 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $83.24 | General |
| Category: NEPHROLOGY | ||||||
| 06/03/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $117.39 | General |
| Category: Cardio-renal | ||||||
| 11/12/2021 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $42.62 | General |
| 11/11/2021 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $115.97 | General |
| 10/21/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,334.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/31/2021 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| 10/11/2020 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| 09/30/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $778.00 | General |
| 09/29/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $973.00 | General |
| 08/06/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/22/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,556.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/08/2020 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 05/17/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,403.75 | General |
| 03/16/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/12/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $89.98 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/12/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $47.15 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/27/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/27/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,556.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/20/2020 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $122.42 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/30/2020 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $95.02 | General |
| Category: NEPHROLOGY | ||||||
| 01/24/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $517.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/24/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $515.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $1,311 | 15 |
| PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE DD-CKD INNO2VATE - CORRECTIONCONVERSION | Otsuka Pharmaceutical Co., Ltd. | $949.78 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 211 | 447 | $208,688 | $69,283 |
| 2022 | 7 | 219 | 444 | $216,545 | $71,973 |
| 2021 | 9 | 258 | 525 | $214,996 | $84,152 |
| 2020 | 11 | 290 | 625 | $234,403 | $79,490 |
Total Patients
978
Total Services
2,041
Medicare Billing
$304,898
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 15 | 119 | $98,934 | $33,674 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 90 | 159 | $47,691 | $14,145 | 29.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 88 | $21,274 | $8,420 | 39.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 14 | 24 | $16,472 | $5,486 | 33.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 32 | $14,540 | $4,462 | 30.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $9,777 | $3,096 | 31.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 16 | 130 | $108,882 | $36,973 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 156 | $47,420 | $14,515 | 30.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 16 | 32 | $22,197 | $7,789 | 35.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 40 | 70 | $16,716 | $5,702 | 34.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $9,245 | $3,227 | 34.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $9,058 | $2,870 | 31.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 13 | 13 | $3,027 | $894.67 | 29.6% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 17 | 159 | $111,330 | $46,921 | 42.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 106 | $28,779 | $10,542 | 36.6% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 16 | 30 | $17,595 | $7,029 | 39.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 63 | $15,393 | $5,259 | 34.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 28 | 30 | $14,254 | $4,935 | 34.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 58 | $10,305 | $3,509 | 34.0% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 15 | 41 | $7,093 | $2,466 | 34.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $6,658 | $2,252 | 33.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 21 | $3,588 | $1,240 | 34.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 23 | 194 | $130,368 | $44,738 | 34.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 90 | 155 | $27,280 | $8,415 | 30.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 32 | 36 | $17,172 | $5,899 | 34.4% |
About Dr. Douglas Shemin, MD
Dr. Douglas Shemin, MD is a Nephrology healthcare provider based in Riverside, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710934724.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Douglas Shemin, MD has received a total of $36,310 in payments from pharmaceutical and medical device companies, with $122.53 received in 2024. These payments were reported across 70 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14,550).
As a Medicare-enrolled provider, Shemin has provided services to 978 Medicare beneficiaries, totaling 2,041 services with total Medicare billing of $304,898. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Riverside, RI
- Active Since 05/27/2006
- Last Updated 11/18/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1710934724
Products in Payments
- LOKELMA (Drug) $14,249
- Parsabiv (Biological) $7,305
- Sensipar (Drug) $4,187
- JYNARQUE (Drug) $282.03
- ACTHAR (Biological) $124.60
- ELIQUIS (Drug) $122.42
- Kerendia (Drug) $117.39
- Parsabiv (Drug) $103.67
- Rayaldee (Drug) $25.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Riverside
Reginald Gohh, Md, MD
Nephrology — Payments: $65,346
Nephrology $65,346
Dr. Ankur Shah, M.d, M.D
Nephrology — Payments: $26,029
Nephrology $26,029
Joseph Lee, M.d, M.D
Nephrology — Payments: $18,723
Nephrology $18,723
Dr. Jie Tang, Md, Ms, Mph, MD, MS, MPH
Nephrology — Payments: $16,418
Nephrology $16,418
Dr. Dalia Zaky Dawoud, Md, MD
Nephrology — Payments: $11,089
Nephrology $11,089
Salam Ishak, M.d, M.D
Nephrology — Payments: $5,994
Nephrology $5,994